Skip to main content
Premium Trial:

Request an Annual Quote

Quest Completes Athena Deal

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today announced the completion of its acquisition of Athena Diagnostics from Thermo Fisher Scientific.

The $740 million deal was announced in late February.

Athena will continue to operate under its own name as an independent business within Quest, and its clinical laboratory in Worcester, Mass., is now the center of excellence in neurology diagnostics for Quest, the Madison, N.J.-based diagnostics testing firm said.

"With this acquisition, Quest Diagnostics has clearly established the leading position in the neurology diagnostics market, "Surya Mohapatra, chairman and CEO of Quest, said in a statement.

Athena generated about $110 million in revenues in 2010 and was part of Thermo Fisher's specialty diagnostics business within its Analytical Technologies segment.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.